Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lucid Diagnostics (LUCD) Share-based Compensation (2021 - 2025)

Lucid Diagnostics' Share-based Compensation history spans 5 years, with the latest figure at $1.3 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 7.94% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $4.6 million, up 1.24%, while the annual FY2025 figure was $4.5 million, 0.95% down from the prior year.
  • Share-based Compensation reached $1.3 million in Q4 2025 per LUCD's latest filing, up from $1.2 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $3.8 million in Q2 2022 to a low of $748000.0 in Q4 2023.
  • Average Share-based Compensation over 5 years is $1.9 million, with a median of $1.3 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: surged 339.38% in 2022, then crashed 71.32% in 2023.
  • A 5-year view of Share-based Compensation shows it stood at $3.4 million in 2021, then decreased by 24.25% to $2.6 million in 2022, then plummeted by 71.32% to $748000.0 in 2023, then skyrocketed by 56.55% to $1.2 million in 2024, then increased by 7.94% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for LUCD's Share-based Compensation are $1.3 million (Q4 2025), $1.2 million (Q3 2025), and $1.1 million (Q2 2025).